Skyhawk SKY-0515 Update
Jan. 27, 2026 – Today Skyhawk Therapeutics Inc. announced encouraging interim results concerning SKY-0515, an investigational medicine being studied for
Read more
uniQure AMT-130 Updates
Nov. 3, 2025 – uniQure released an update on discussions with the FDA about AMT-130, an investigational one-time gene therapy
Read more
Researchers tackle major health challenges with $16 million in funding from CIHR
Feb. 5, 2025 – We are excited to follow the research of Dr. O’Donoghue, our HSC Research Chair, as he
Read more
$1.2 Million Invested in Huntington Disease Research
Monday, January 20 – The Huntington Society of Canada (HSC), Brain Canada, and the River Philip Foundation are pleased to
Read more
Valbenazine approved by U.S. FDA for treatment of chorea in HD
Neurocrine Biosciences, Inc. announced the U.S. Food and Drug Administration (FDA) has approved INGREZZA ® (Valbenazine) capsules for treatment of
Read more
Update from Prilenia Regarding PROOF-HD Clinical Trials
Dear Huntington disease (HD) community, We have received an update on PROOF-HD, the phase 3, randomized, double-blind, placebo-controlled study to
Read more
One million reasons to smile
Do you like feel-good news? We know you’ll love this fabulous Huntington disease (HD) update. Thanks to our generous donors,
Read more
Novartis VIBRANT-HD Update
Update From Novartis Regarding VIBRANT-HD Clinical Trials – December 8, 2022 Dear Huntington disease (HD) community, We have received a
Read more
Promising results from SELECT-HD trial
SELECT-HD Trial Update – September 22, 2022 Dear HD Community, We are pleased to announce that Wave Life Sciences has
Read more
Announcing new Phase II clinical study, GENERATION HD 2
ANNOUNCING GENERATION HD2 – 21 September 2022 Dear HD community, We are pleased to share that Roche and Genentech have
Read more
- 1
- 2
- 3
- …
- 13
- Next Page »